Education
About Us
Working with TipRanks
Follow Us
DaVita (DVA)
NYSE:DVA
DVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$126.07 - $179.60
Previous CloseN/A
Volume85.32K
Average Volume (3M)845.25K
Market Cap
$9.23B
Enterprise Value$24.93B
Total Cash (Recent Filing)$739.43M
Total Debt (Recent Filing)$12.20B
Price to Earnings (P/E)12.7
Beta0.60
Next Earnings
Oct 29, 2025EPS Estimate
3.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.95
Shares Outstanding71,500,000
10 Day Avg. Volume1,047,035
30 Day Avg. Volume845,254
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)104.94
Price to Sales (P/S)0.99
P/FCF Ratio8.67
Enterprise Value/Market Cap2.70
Enterprise Value/Revenue1.89
Enterprise Value/Gross Profit7.88
Enterprise Value/Ebitda10.02
Forecast
1Y Price Target
$147.00Price Target Upside13.91% Upside
Rating ConsensusHold
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Operating IncomeOperating income for the first quarter was 5% better than expected, thanks to improved margins.
Oral Phosphate BindersInclusion of oral phosphate binders is expected to provide a potential operating income benefit, with the midpoint considered most likely.
Bears Say
Cyberattack ImpactExpectations of lower treatment volumes and lost admissions due to a cyber incident are impacting forecasts.
Volume GrowthThe continued tepid volume growth is weighing on shares and will likely continue to be the main investor debate.
DaVita News
DVA FAQ
What was DaVita’s price range in the past 12 months?
DaVita lowest stock price was $126.07 and its highest was $179.60 in the past 12 months.
What is DaVita’s market cap?
DaVita’s market cap is $9.23B.
When is DaVita’s upcoming earnings report date?
DaVita’s upcoming earnings report date is Oct 29, 2025 which is in 77 days.
How were DaVita’s earnings last quarter?
DaVita released its earnings results on Aug 05, 2025. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.771 by $0.179.
Is DaVita overvalued?
According to Wall Street analysts DaVita’s price is currently Undervalued.
Does DaVita pay dividends?
DaVita does not currently pay dividends.
What is DaVita’s EPS estimate?
DaVita’s EPS estimate is 3.23.
How many shares outstanding does DaVita have?
DaVita has 71,500,000 shares outstanding.
What happened to DaVita’s price movement after its last earnings report?
DaVita reported an EPS of $2.95 in its last earnings report, beating expectations of $2.771. Following the earnings report the stock price went down -9.045%.
Which hedge fund is a major shareholder of DaVita?
Currently, no hedge funds are holding shares in DVA
DaVita Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$147.00 (13.91% Upside)
$147.00 (13.91% Upside)
Blogger Sentiment
Bullish
DVA Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.01%
12-Months-Change
Fundamentals
Return on Equity
635.30%
Trailing 12-Months
Asset Growth
2.75%
Trailing 12-Months
Company Description
DaVita
DaVita Inc. is a leading provider of kidney care and dialysis services in the United States and internationally. The company operates a vast network of outpatient dialysis centers, offering treatments to patients with chronic kidney failure and end-stage renal disease (ESRD). In addition to dialysis services, DaVita also provides various ancillary services, including nutritional support and education for patients, as well as managing care for patients with related health issues. The company's commitment to patient care and innovation in renal health solutions positions it as a significant player in the healthcare sector.
DVA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong cost management and financial performance exceeding expectations, despite challenges from a recent cyber incident and elevated mortality rates. While DaVita demonstrated resilience and strategic progress, there are ongoing issues with treatment volumes and adherence to new pharmaceutical protocols.View all DVA earnings summariesDVA Revenue Breakdown
88.32% U.S. dialysis
11.68% Ancillary services
DVA Stock 12 Month Forecast
Average Price Target
$147.00
▲(13.91% Upside)
Technical Analysis
Chemed
―
Fresenius Medical Care
―
Encompass Health
―
Tenet Healthcare
―
Universal Health
―
Ownership Overview
46.90% Insiders
10.46% Mutual Funds
0.63% Other Institutional Investors
23.38% Public Companies and
Individual Investors